ArticleJournal of clinical microbiology2026
Development of a broad-lineage Lassa virus rapid diagnostic test informed by the WHO REASSURED framework.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lassa fever is a high-risk viral disease endemic to West Africa for which rapid and reliable diagnosis is essential for outbreak control. Here, we describe the development of a lateral flow-based rapid diagnostic test (RDT) targeting the Lassa virus nucleoprotein using newly generated monoclonal antibody pairs. The analytical performance of the assay was evaluated using human serum and plasma specimens as well as inactivated Lassa virus strains and compared with a commercially available antigen test. The final RDT (Pair 2; 1P-44-7/9B-28) demonstrated high analytical sensitivity and 100% specificity across 60 human samples and detected multiple genetically diverse Lassa virus strains, with lineage-dependent differences in analytical sensitivity. In direct analytical comparisons using recombinant antigen, the assay was approximately 64-fold more sensitive than the ReLASV Pan-Lassa Antigen Rapid Test. The RDT provides a rapid visual readout, remains stable at ambient temperatures, and is suitable for decentralized testing workflows, features aligned with key aspects of the World Health Organization (WHO) REASSURED framework. These results indicate that the developed RDT offers a robust and broadly reactive platform for Lassa virus antigen detection and has potential utility for surveillance and outbreak response in resource-limited settings.IMPORTANCELassa fever remains a significant public health concern in West Africa, where diagnostic capacity is often limited in endemic regions. This study describes the development of a broad-lineage Lassa virus rapid diagnostic test informed by the World Health Organization (WHO) REASSURED framework. The assay demonstrates high analytical sensitivity and broad lineage coverage in a field-deployable format, supporting its potential utility for early case detection and decentralized surveillance in endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.